Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib

Blood

Volumn 123, Issue 23, 2014, Pages 3574-3577

  Cheah, Chan Y ^a,b   Burbury, Kate ^a,b   Apperley, Jane F ^c   Huguet, Francoise ^d   Pitini, Vincenzo ^e   Gardembas, Martine ^f   Ross, David M ^g,h,i   Forrest, Donna ^j   Genet, Philippe ^k   Rousselot, Philippe ^l   Patton, Nigel ^m   Smith, Graeme ⁿ   Dunbar, Cynthia E ^o   Ito, Sawa ^o   Aguiar, Ricardo C T ^p,q   Odenike, Olatoyosi ^r   Gimelfarb, Alla ^s   Cross, Nicholas C P ^t   Seymour, John F ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

^e Oncologia Medica e Trapianto di Midollo Osseo   (Italy)

^f ANGERS UNIVERSITY HOSPITAL   (France)

^g Haematology Department   (Australia)

^h UNIVERSITY OF ADELAIDE   (Australia)

ⁱ FLINDERS UNIVERSITY   (Australia)

^j BRITISH COLUMBIA CANCER AGENCY   (Canada)

^k CENTRE HOSPITALIER VICTOR DUPOUY   (France)

^l LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^m AUCKLAND CITY HOSPITAL   (New Zealand)

ⁿ ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^o NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^p Mays Cancer Center at UT Health San Antonio   (United States)

^q SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^r SECTION OF HEMATOLOGY ONCOLOGY   (United States)

^s NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^t UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CLADRIBINE; CYTARABINE; DAUNORUBICIN; HYDROXYUREA; IMATINIB; PREDNISOLONE; TRANSCRIPTION FACTOR ETV6;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BIN2 GENE; BLAST CELL CRISIS; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHILD; CHROMOSOME ANALYSIS; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; EOSINOPHILIA; FOLLOW UP; FUSION GENE; GENE REARRANGEMENT; HEMATOLOGIC DISEASE; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA REMISSION; MYALGIA; MYCOSIS; MYELOPROLIFERATIVE NEOPLASM; OVERALL SURVIVAL; PDE4DIP GENE; PDGFRB GENE; PRIORITY JOURNAL; PRKG2 GENE; PROGRESSION FREE SURVIVAL; RAB5EP GENE; RETROSPECTIVE STUDY; SHORT STATURE; SPTBN1 GENE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GENE; WDR48 GENE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZAMIDES; CHILD; CHILD, PRESCHOOL; EOSINOPHILIA; FEMALE; HUMANS; INFANT; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; PIPERAZINES; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; REMISSION INDUCTION; TRANSLOCATION, GENETIC; YOUNG ADULT;

EID: 84902168976     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-02-555607     Document Type: Article

References (25)

1. Havelange V, Demoulin JB. Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia. J Blood Med. 2013;4:111-121.
2. Arefi M, García JL, Peñarrubia MJ, et al. Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement. Eur J Haematol. 2012;89(1):37-41.
3. Lengline E, Beldjord K, Dombret H, Soulier J, Boissel N, Clappier E. Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion. Haematologica. 2013;98(11): e146-e148.
4. Tokita K, Maki K, Tadokoro J, et al. Chronic idiopathic myelofibrosis expressing a novel type of TEL-PDGFRB chimaera responded to imatinib mesylate therapy. Leukemia. 2007;21(1):190-192. (Pubitemid 44921858)
5. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994;77(2):307-316. (Pubitemid 24138627)
6. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002;347(7): 481-487. (Pubitemid 34879335)
7. David M, Cross NC, Burgstaller S, et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood. 2007; 109(1):61-64. (Pubitemid 46053044)
8. Magnusson MK, Meade KE, Nakamura R, Barrett J, Dunbar CE. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. Blood. 2002;100(3):1088-1091. (Pubitemid 34832647)
9. Pitini V, Arrigo C, Teti D, Barresi G, Righi M, Alo G. Response to STI571 in chronic myelomonocytic leukemia with platelet derived growth factor beta receptor involvement: a new case report. Haematologica. 2003;88(5):ECR18.
10. Wilkinson K, Velloso ER, Lopes LF, et al. Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. Blood. 2003;102(12):4187-4190. (Pubitemid 37487006)
11. Bastie JN, Garcia I, Terré C, Cross NC, Mahon FX, Castaigne S. Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor betagene. Haematologica. 2004;89(10):1263-1264. (Pubitemid 39390454)
12. Curtis CE, Grand FH, Waghorn K, Sahoo TP, George J, Cross NC. A novel ETV6-PDGFRB fusion transcript missed by standard screening in a patient with an imatinib responsive chronic myeloproliferative disease. Leukemia. 2007; 21(8):1839-1841. (Pubitemid 47086780)
13. Gallagher G, Horsman DE, Tsang P, Forrest DL. Fusion of PRKG2 and SPTBN1 to the plateletderived growth factor receptor beta gene (PDGFRB) in imatinib-responsive atypical myeloproliferative disorders. Cancer Genet Cytogenet. 2008;181(1):46-51. (Pubitemid 351200520)
14. Garcia JL, Font de Mora J, Hernandez JM, et al. Imatinib mesylate elicits positive clinical response in atypical chronic myeloid leukemia involving the platelet-derived growth factor receptor beta. Blood. 2003;102(7):2699-2700. (Pubitemid 37193619)
15. Levine RL, Wadleigh M, Sternberg DW, et al. KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32). Leukemia. 2005;19(1):27-30. (Pubitemid 40090071)
16. Vizmanos JL, Novo FJ, Román JP, et al. NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder. Cancer Res. 2004; 64(8):2673-2676. (Pubitemid 38500599)
17. Walz C, Haferlach C, Hänel A, et al. Identification of a MYO18A-PDGFRB fusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2). Genes Chromosomes Cancer. 2009;48(2):179-183.
18. Steer EJ, Cross NC. Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta. Acta Haematol. 2002;107(2):113-122. (Pubitemid 34264176)
19. Helbig G, Stella-Holowiecka B, Majewski M, et al. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRAexpressing patients. Br J Haematol. 2008;141(2): 200-204. (Pubitemid 351406214)
20. Baccarani M, Cilloni D, Rondoni M, et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica. 2007;92(9):1173- 1179.
21. Pardanani A, D'Souza A, Knudson RA, Hanson CA, Ketterling RP, Tefferi A. Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome. Leukemia. 2012;26(11):2439-2441.
22. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348(13):1201-1214. (Pubitemid 36359296)
23. White D, Saunders V, Lyons AB, et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood. 2005;106(7): 2520-2526. (Pubitemid 41510828)
24. Mahon FX, Réa D, Guilhot J, et al; Intergroupe Français des Leucémies Myéloïdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11): 1029-1035.
25. Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122(4):515-522.